These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 1663044

  • 1. Vasoactive intestinal peptide receptor antagonists in rat seminal vesicle membranes.
    Rodríguez-Pena MS, Guijarro LG, Prieto JC.
    Eur J Pharmacol; 1991 Nov 13; 208(3):207-12. PubMed ID: 1663044
    [Abstract] [Full Text] [Related]

  • 2. Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages.
    Pozo D, Montilla ML, Guerrero JM, Calvo JR.
    Eur J Pharmacol; 1997 Mar 05; 321(3):379-86. PubMed ID: 9085051
    [Abstract] [Full Text] [Related]

  • 3. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.
    Waelbroeck M, Robberecht P, Coy DH, Camus JC, De Neef P, Christophe J.
    Endocrinology; 1985 Jun 05; 116(6):2643-9. PubMed ID: 2859987
    [Abstract] [Full Text] [Related]

  • 4. The entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide receptor: functional and binding studies on opossum internal anal sphincter smooth muscle.
    Chakder S, Rattan S.
    J Pharmacol Exp Ther; 1993 Jul 05; 266(1):392-9. PubMed ID: 8392560
    [Abstract] [Full Text] [Related]

  • 5. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
    Laburthe M, Couvineau A, Rouyer-Fessard C.
    Mol Pharmacol; 1986 Jan 05; 29(1):23-7. PubMed ID: 3003561
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Interaction of ovine pituitary adenylate cyclase-activating peptide (PACAP-38) with rat lung membranes.
    Bitar KG, Coy DH.
    Peptides; 1993 Jan 05; 14(3):621-7. PubMed ID: 8392724
    [Abstract] [Full Text] [Related]

  • 9. Interaction of vasoactive intestinal peptide (VIP) and N-terminally modified VIP analogs with rat pancreatic, hepatic and pituitary membranes.
    Robberecht P, Coy DH, De Neef P, Camus JC, Cauvin A, Waelbroeck M, Christophe J.
    Eur J Biochem; 1986 Aug 15; 159(1):45-9. PubMed ID: 3017717
    [Abstract] [Full Text] [Related]

  • 10. Heart receptors for VIP, PHI and secretin are able to activate adenylate cyclase and to mediate inotropic and chronotropic effects. Species variations and physiopathology.
    Christophe J, Waelbroeck M, Chatelain P, Robberecht P.
    Peptides; 1984 Aug 15; 5(2):341-53. PubMed ID: 6089134
    [Abstract] [Full Text] [Related]

  • 11. Effects of vasoactive intestinal polypeptide antagonists on cholinergic neurotransmission in dog and cat trachea.
    Xie ZQ, Hirose T, Hakoda H, Ito Y.
    Br J Pharmacol; 1991 Dec 15; 104(4):938-44. PubMed ID: 1667294
    [Abstract] [Full Text] [Related]

  • 12. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas.
    Le Meuth V, Farjaudon N, Bawab W, Chastre E, Rosselin G, Guilloteau P, Gespach C.
    Am J Physiol; 1991 Feb 15; 260(2 Pt 1):G265-74. PubMed ID: 1847591
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Lack of effect of vasoactive intestinal peptide antagonists on blood flow in the rat thyroid.
    Michalkiewicz M, Huffman LJ, Hedge GA.
    Peptides; 1991 Feb 15; 12(6):1181-6. PubMed ID: 1815206
    [Abstract] [Full Text] [Related]

  • 15. Adenylyl cyclase stimulation by VIP in rat seminal vesicle membranes.
    Rodriguez-Pena MS, Guijarro LG, Prieto JC.
    Peptides; 1991 Feb 15; 12(4):821-4. PubMed ID: 1664946
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.